Two diabetes-related news items have been observed: Nemaura Medical announced it has filed a PMA with FDA for its sugarBEAT non-invasive CGM and Medtronic launched the Mio Advance infusion set in the US. In conjunction with the Nemaura filing announcement, the company also hosted a call with investors discussing the company’s commercial efforts (US and ex-US), partnership opportunities, and development of a new continuous temperature monitor. Below, FENIX provides highlights and insights relating to the sugarBEAT PMA submission as well as brief thoughts on the new Medtronic infusion set.